GS-2829 and GS-6779 HBV therapeutic vaccine generates robust, polyfunctional, genotype cross-reactive CD8 T cell responses accompanied by high titers of anti-HBsAg antibodies

Conference Reports for NATAP

The Liver Meeting
Digital Experience
AASLD
Washington on 04-08
November 2022


GS-2829 and GS-6779 HBV therapeutic vaccine generates robust, polyfunctional, genotype cross-reactive CD8 T cell responses accompanied by high titers of anti-HBsAg antibodiess

	AASLD 2022 Nov 4-8